An Advax-CpG55.2™ adjuvanted recombinant spike protein vaccine protects cynomolgus macaques from a homologous SARS-CoV-2 virus challenge

[1]  S. Lal,et al.  Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies , 2023, Viruses.

[2]  N. Petrovsky,et al.  Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2–adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial , 2022, Clinical Microbiology and Infection.

[3]  D. Barouch,et al.  T cell immunity to COVID-19 vaccines , 2022, Science.

[4]  N. Petrovsky,et al.  Covax-19/Spikogen® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters , 2022, Vaccine.

[5]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, Nature.

[6]  Fei Shao,et al.  Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies , 2021, bioRxiv.

[7]  N. Petrovsky,et al.  Artificial Intelligence in Vaccine and Drug Design. , 2021, Methods in molecular biology.

[8]  N. Petrovsky,et al.  An Advax-Adjuvanted Inactivated Cell-Culture Derived Japanese Encephalitis Vaccine Induces Broadly Neutralising Anti-Flavivirus Antibodies, Robust Cellular Immunity and Provides Single Dose Protection , 2021, Vaccines.

[9]  Y. Kawaoka,et al.  COVID-19 cynomolgus macaque model reflecting human COVID-19 pathological conditions , 2021, Proceedings of the National Academy of Sciences.

[10]  Manfred S. Green,et al.  Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel , 2021, The New England journal of medicine.

[11]  N. Petrovsky,et al.  A truncated glycoprotein G vaccine formulated with Advax-CpG adjuvant provides protection of mice against genital herpes simplex virus 2 infection. , 2021, Vaccine.

[12]  Hua Huang,et al.  Respiratory epithelial cell responses to SARS-CoV-2 in COVID-19 , 2021, Thorax.

[13]  N. Petrovsky,et al.  A M2 protein-based universal influenza vaccine containing Advax-SM adjuvant provides newborn protection via maternal or neonatal immunization. , 2021, Vaccine.

[14]  N. Petrovsky,et al.  Immunisation of ferrets and mice with recombinant SARS-CoV-2 spike protein formulated with Advax-SM adjuvant protects against COVID-19 infection , 2021, bioRxiv.

[15]  J. Nkengasong,et al.  COVID-19 vaccine access in Africa: Global distribution, vaccine platforms, and challenges ahead , 2021, Immunity.

[16]  P. Kalra,et al.  Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine , 2021, The New England journal of medicine.

[17]  R. Kim,et al.  Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. , 2021, JAMA cardiology.

[18]  N. Javed,et al.  COVID-19 Vaccination in Developing Nations: Challenges and Opportunities for Innovation , 2021, Infectious disease reports.

[19]  N. Petrovsky,et al.  Advax-CpG Adjuvant Provides Antigen Dose-Sparing and Enhanced Immunogenicity for Inactivated Poliomyelitis Virus Vaccines , 2021, Pathogens.

[20]  F. Derosa,et al.  Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models , 2021, npj Vaccines.

[21]  F. Derosa,et al.  Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models , 2021, NPJ vaccines.

[22]  G. Vogel,et al.  Side effect worry grows for AstraZeneca vaccine. , 2021, Science.

[23]  Hannah Ritchie,et al.  A global database of COVID-19 vaccinations , 2021, Nature Human Behaviour.

[24]  A. Fiore-Gartland,et al.  Evidence for antibody as a protective correlate for COVID-19 vaccines , 2021, Vaccine.

[25]  A. Nicholson,et al.  Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19 , 2021, Nature Communications.

[26]  T. Shimabukuro,et al.  Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine. , 2021, JAMA.

[27]  C. Demirdover.  COVID-19-vaccines , 2021, Reactions Weekly.

[28]  P. Brodin.  Immune determinants of COVID-19 disease presentation and severity , 2021, Nature Medicine.

[29]  A. Tzankov,et al.  The pulmonary pathology of COVID-19 , 2021, Virchows Archiv.

[30]  A. Iafrate,et al.  COVID-19-neutralizing antibodies predict disease severity and survival , 2020, Cell.

[31]  J. Kaiser.  Temperature concerns could slow the rollout of new coronavirus vaccines , 2020 .

[32]  S. Kent,et al.  Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies , 2020, Nature Microbiology.

[33]  Rebecca J. Loomis,et al.  SARS-CoV-2 mRNA Vaccine Design Enabled by Prototype Pathogen Preparedness , 2020, Nature.

[34]  V. Munster,et al.  ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques , 2020, Nature.

[35]  N. Petrovsky,et al.  Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection , 2020, Frontiers in Immunology.

[36]  H. Mouquet,et al.  Syncytia formation by SARS‐CoV‐2‐infected cells , 2020, bioRxiv.

[37]  L. Renault,et al.  Stabilizing the closed SARS-CoV-2 spike trimer , 2020, Nature Communications.

[38]  D. Burton,et al.  Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model , 2020, Science.

[39]  R. Baric,et al.  DNA vaccine protection against SARS-CoV-2 in rhesus macaques , 2020, Science.

[40]  Xiangxi Wang,et al.  Development of an inactivated vaccine candidate for SARS-CoV-2 , 2020, Science.

[41]  A. De Grassi,et al.  Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies , 2020, Cellular and Molecular Life Sciences.

[42]  Nikolai Petrovsky,et al.  Prediction of novel mouse TLR9 agonists using a random forest approach , 2019, BMC Molecular and Cell Biology.

[43]  N. Petrovsky,et al.  Efficacy of an Adjuvanted Middle East Respiratory Syndrome Coronavirus Spike Protein Vaccine in Dromedary Camels and Alpacas , 2019, Viruses.

[44]  J. Mattison,et al.  An overview of nonhuman primates in aging research , 2017, Experimental Gerontology.

[45]  N. Petrovsky,et al.  Advax™, a novel microcrystalline polysaccharide particle engineered from delta inulin, provides robust adjuvant potency together with tolerability and safety , 2015, Vaccine.

[46]  N. Petrovsky,et al.  Delta Inulin Adjuvant Enhances Plasmablast Generation, Expression of Activation-Induced Cytidine Deaminase and B-Cell Affinity Maturation in Human Subjects Receiving Seasonal Influenza Vaccine , 2015, PloS one.

[47]  N. Petrovsky,et al.  Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology , 2014, Journal of Virology.

[48]  D. Cassidy-Hanley,et al.  Recombinant subunit vaccines: potentials and constraints. , 2005, Developments in biologicals.